Navigation Links
Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results
Date:8/11/2009

BEIJING, Aug. 11 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, today announced that it will host a conference call on Wednesday, August 19, 2009 at 8:00 a.m. ET to review the Company's second quarter financial results for the period ended June 30, 2009 and provide an update on recent corporate developments.

To access the conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international). A replay of the call will be available from 11:00 a.m. ET on August 19, 2009 to September 2, 2009 at midnight. To access the replay, please dial 1-877-660-6853 (USA) or 1-201-612-7415 (international) and reference the account number 3055 and the access code 330444.

A live audio webcast of the call will also be available from the Investors section on the corporate web site at http://www.sinovac.com . A webcast replay can be accessed on the corporate website beginning August 19, 2009 and the replay will remain available for 30 days.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for Enterovirus 71, Universal Pandemic Influenza, Japanese encephalitis vaccine, and Human Rabies vaccine. Its wholly-owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

    For more information, please contact:

    Contact Information:
     Helen G. Yang
     Sinovac Biotech Ltd.
     Phone: +86-10-8289-0088 x871
     Fax:   +86-10-6296-6910
     Email: info@sinovac.com

    Investors:
     Amy Glynn/Sara Ephraim
     The Ruth Group
     Tel:   +1-646-536-7023/7002
     Email: aglynn@theruthgroup.com
            sephraim@theruthgroup.com

    Media:
     Janine McCargo
     The Ruth Group
     Tel:   +1-646-536-7033
     Email: jmccargo@theruthgroup.com

'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
2. Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
3. Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1)
4. Sinovac Adjourns 2008 Annual General Meeting
5. Sinovac Receives Chinas First Influenza A (H1N1) Vaccine Order
6. Sinovac Completes Construction of H1N1 Virus Seed Bank
7. Sinovac Begins the Production of Influenza A (H1N1) Vaccine
8. Chinas Vice Premier, Li Keqiang, Visits Sinovac to Inspect H1N1 Vaccine Production Preparation
9. Sinovac to Host Conference Call to Report First Quarter 2009 Financial Results
10. Sinovac Biotech Ltd. Files Annual Report on Form 20-F
11. Sinovac Initiates Preparatory Activities for Swine Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... attention to Agenus Inc. (NASDAQ: AGEN), Intrexon Corp. (NYSE: ... Corp. (NASDAQ: CXRX ). According an article ... sector to "Overweight" from "Market Weight" on Tuesday, March 21 st ... by simply registering for free at: ...
(Date:3/29/2017)... 2017  Vermillion, Inc. (NASDAQ: VRML), a bio-analytical ... its results for the fourth quarter and full ... marked a pivotal year for us with our ... distribution agreements, major reimbursement progress with Medicare, positive ... In addition we cleared our 2 nd ...
(Date:3/29/2017)... TIKVAH, Israel , March ... (NASDAQ: BCLI), a leading developer of adult ... financial results for the year ended December ... highly successful and pivotal year for Brainstorm, with a ... made on clinical, regulatory and operational fronts," said ...
(Date:3/29/2017)... ... 2017 , ... On the heels of the globally recognized Rare Disease ... announced that it will manage travel services for its 500th clinical trial this month. ... States and Europe to offer travel management services specifically for clinical trials and their ...
Breaking Biology Technology:
(Date:2/28/2017)... News solutions for biometrics, bag drop and New ADA-compliant kiosk ... At PTE 2017 ... Materna will present its complete end-to-end passenger journey, from ... benefit for passengers. To accelerate the whole passenger handling process, ... to take passengers through the complete integrated process with a ...
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader of ... elite iris biometric solution on the latest Qualcomm® ... at Mobile World Congress 2017 (February 27 ... in Hall 3, Stand 3E10. ... Haven™ security platform—a combination of hardware, software ...
(Date:2/16/2017)... Feb. 16, 2017  Genos, a community for ... it has received Laboratory Accreditation from the College ... presented to laboratories that meet stringent requirements around ... rigorous processes. "Genos is committed to ... practices. We,re honored to be receiving CAP accreditation," ...
Breaking Biology News(10 mins):